Selected research
Market Structure
Global Circulating Biomarker Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Circulating Biomarker market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Circulating Biomarker is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Circulating Biomarker is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Circulating Biomarker is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Circulating Biomarker is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Circulating Biomarker include GE Healthcare, Fluxion Biosciences, Epigenomics AG, Biocept, Becton, Dickinson and Company, Agilent Technologies, Affymetrix and Abbott Laboratories, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Circulating Biomarker market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Circulating Biomarker and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Circulating Biomarker sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Circulating Biomarker market size, projected growth trends, production technologies, key applications, and end-use industries.
Circulating Biomarker Segment by Company
GE Healthcare
Fluxion Biosciences
Epigenomics AG
Biocept
Becton, Dickinson and Company
Agilent Technologies
Affymetrix
Abbott Laboratories
Circulating Biomarker Segment by Type
Circulating DNA
Circulating Tumor Cells
Other
Circulating Biomarker Segment by Application
Early Cancer Screening
Therapy Selection
Treatment Monitoring
Recurrence Monitoring Orthopedics
Circulating Biomarker Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Circulating Biomarker market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Circulating Biomarker and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Circulating Biomarker.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Circulating Biomarker market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Circulating Biomarker manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Circulating Biomarker in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Circulating Biomarker in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Circulating DNA
- Circulating Tumor Cells
- Other
Applications
- Early Cancer Screening
- Therapy Selection
- Treatment Monitoring
- Recurrence Monitoring Orthopedics
Companies covered
- GE Healthcare
- Fluxion Biosciences
- Epigenomics AG
- Biocept
- Becton, Dickinson and Company
- Agilent Technologies
- Affymetrix
- Abbott Laboratories
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Circulating Biomarker Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Circulating Biomarker Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Circulating Biomarker Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Circulating Biomarker Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Circulating Biomarker Market Dynamics
- 2.1 Circulating Biomarker Industry Trends
- 2.2 Circulating Biomarker Industry Drivers
- 2.3 Circulating Biomarker Industry Opportunities and Challenges
- 2.4 Circulating Biomarker Industry Restraints
3 Circulating Biomarker Market by Manufacturers
- 3.1 Global Circulating Biomarker Revenue by Manufacturers (2021-2026)
- 3.2 Global Circulating Biomarker Sales by Manufacturers (2021-2026)
- 3.3 Global Circulating Biomarker Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Circulating Biomarker Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Circulating Biomarker Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Circulating Biomarker Manufacturers, Product Type & Application
- 3.7 Global Circulating Biomarker Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Circulating Biomarker Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Circulating Biomarker Players Market Share by Revenue in 2025
- 3.8.3 2025 Circulating Biomarker Tier 1, Tier 2, and Tier 3
4 Circulating Biomarker Market by Type
- 4.1 Circulating Biomarker Type Introduction
- 4.1.1 Circulating DNA
- 4.1.2 Circulating Tumor Cells
- 4.1.3 Other
- 4.2 Global Circulating Biomarker Sales by Type
- 4.2.1 Global Circulating Biomarker Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Circulating Biomarker Sales by Type (2021-2032)
- 4.2.3 Global Circulating Biomarker Sales Market Share by Type (2021-2032)
- 4.3 Global Circulating Biomarker Revenue by Type
- 4.3.1 Global Circulating Biomarker Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Circulating Biomarker Revenue by Type (2021-2032)
- 4.3.3 Global Circulating Biomarker Revenue Market Share by Type (2021-2032)
5 Circulating Biomarker Market by Application
- 5.1 Circulating Biomarker Application Introduction
- 5.1.1 Early Cancer Screening
- 5.1.2 Therapy Selection
- 5.1.3 Treatment Monitoring
- 5.1.4 Recurrence Monitoring Orthopedics
- 5.2 Global Circulating Biomarker Sales by Application
- 5.2.1 Global Circulating Biomarker Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Circulating Biomarker Sales by Application (2021-2032)
- 5.2.3 Global Circulating Biomarker Sales Market Share by Application (2021-2032)
- 5.3 Global Circulating Biomarker Revenue by Application
- 5.3.1 Global Circulating Biomarker Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Circulating Biomarker Revenue by Application (2021-2032)
- 5.3.3 Global Circulating Biomarker Revenue Market Share by Application (2021-2032)
6 Global Circulating Biomarker Sales by Region
- 6.1 Global Circulating Biomarker Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Circulating Biomarker Sales by Region (2021-2032)
- 6.2.1 Global Circulating Biomarker Sales by Region (2021-2026)
- 6.2.2 Global Circulating Biomarker Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Circulating Biomarker Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Circulating Biomarker Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Circulating Biomarker Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Circulating Biomarker Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Circulating Biomarker Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Circulating Biomarker Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Circulating Biomarker Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Circulating Biomarker Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Circulating Biomarker Revenue by Region
- 7.1 Global Circulating Biomarker Revenue by Region
- 7.1.1 Global Circulating Biomarker Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Circulating Biomarker Revenue by Region (2021-2026)
- 7.1.3 Global Circulating Biomarker Revenue by Region (2027-2032)
- 7.1.4 Global Circulating Biomarker Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Circulating Biomarker Revenue (2021-2032)
- 7.2.2 North America Circulating Biomarker Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Circulating Biomarker Revenue (2021-2032)
- 7.3.2 Europe Circulating Biomarker Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Circulating Biomarker Revenue (2021-2032)
- 7.4.2 Asia-Pacific Circulating Biomarker Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Circulating Biomarker Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Circulating Biomarker Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 GE Healthcare
- 8.1.1 GE Healthcare Company Information
- 8.1.2 GE Healthcare Business Overview
- 8.1.3 GE Healthcare Circulating Biomarker Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 GE Healthcare Circulating Biomarker Product Portfolio
- 8.1.5 GE Healthcare Recent Developments
- 8.2 Fluxion Biosciences
- 8.2.1 Fluxion Biosciences Company Information
- 8.2.2 Fluxion Biosciences Business Overview
- 8.2.3 Fluxion Biosciences Circulating Biomarker Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Fluxion Biosciences Circulating Biomarker Product Portfolio
- 8.2.5 Fluxion Biosciences Recent Developments
- 8.3 Epigenomics AG
- 8.3.1 Epigenomics AG Company Information
- 8.3.2 Epigenomics AG Business Overview
- 8.3.3 Epigenomics AG Circulating Biomarker Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Epigenomics AG Circulating Biomarker Product Portfolio
- 8.3.5 Epigenomics AG Recent Developments
- 8.4 Biocept
- 8.4.1 Biocept Company Information
- 8.4.2 Biocept Business Overview
- 8.4.3 Biocept Circulating Biomarker Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Biocept Circulating Biomarker Product Portfolio
- 8.4.5 Biocept Recent Developments
- 8.5 Becton, Dickinson and Company
- 8.5.1 Becton, Dickinson and Company Company Information
- 8.5.2 Becton, Dickinson and Company Business Overview
- 8.5.3 Becton, Dickinson and Company Circulating Biomarker Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Becton, Dickinson and Company Circulating Biomarker Product Portfolio
- 8.5.5 Becton, Dickinson and Company Recent Developments
- 8.6 Agilent Technologies
- 8.6.1 Agilent Technologies Company Information
- 8.6.2 Agilent Technologies Business Overview
- 8.6.3 Agilent Technologies Circulating Biomarker Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Agilent Technologies Circulating Biomarker Product Portfolio
- 8.6.5 Agilent Technologies Recent Developments
- 8.7 Affymetrix
- 8.7.1 Affymetrix Company Information
- 8.7.2 Affymetrix Business Overview
- 8.7.3 Affymetrix Circulating Biomarker Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 Affymetrix Circulating Biomarker Product Portfolio
- 8.7.5 Affymetrix Recent Developments
- 8.8 Abbott Laboratories
- 8.8.1 Abbott Laboratories Company Information
- 8.8.2 Abbott Laboratories Business Overview
- 8.8.3 Abbott Laboratories Circulating Biomarker Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 Abbott Laboratories Circulating Biomarker Product Portfolio
- 8.8.5 Abbott Laboratories Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Circulating Biomarker Value Chain Analysis
- 9.1.1 Circulating Biomarker Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Circulating Biomarker Production Mode & Process
- 9.2 Circulating Biomarker Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Circulating Biomarker Distributors
- 9.2.3 Circulating Biomarker Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst